Humacyte Beheer

Beheer criteriumcontroles 3/4

De CEO Humacyte's is Laura Niklason, benoemd in Jan2004, heeft een ambtstermijn van 20.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.63M, bestaande uit 23% salaris en 77% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde $ 1.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 3.2 jaar.

Belangrijke informatie

Laura Niklason

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	23.0%
Dienstverband CEO	20.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14

Humacyte: Intriguing Potential

Oct 13

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Aug 12

Analyse CEO-vergoeding

Hoe is Laura Niklason's beloning veranderd ten opzichte van Humacyte's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$3m	US$604k	-US$111m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$500k	-US$12m
Sep 30 2022	n/a	n/a	US$34m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	US$11m	US$500k	-US$26m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$69m
Dec 31 2020	US$619k	US$75k	-US$67m

Compensatie versus markt: De totale vergoeding ($USD 2.63M ) Laura } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).

Compensatie versus inkomsten: De vergoeding van Laura is gestegen terwijl het bedrijf verliesgevend is.

CEO

Laura Niklason (61 yo)

20.8yrs

Tenure

US$2,625,702

Compensatie

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Laura Niklason	Founder	20.8yrs	US$2.63m	0.19% $ 1.4m
Dale Sander	CFO, Chief Corporate Development Officer & Treasurer	3.9yrs	US$1.35m	0.018% $ 131.6k
Heather Prichard	Chief Operating Officer	5.4yrs	US$1.27m	0% $ 0
Sabrina Osborne	Chief People Officer	no data	geen gegevens	geen gegevens
William Scheessele	Chief Commercial Officer	3.2yrs	geen gegevens	geen gegevens
Shamik Parikh	Chief Medical Officer	2.5yrs	US$1.53m	0% $ 0
Harold Alterson	Chief Quality Officer	2.2yrs	geen gegevens	geen gegevens
Yang Cao	Chief Regulatory Officer	2.1yrs	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HUMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Laura Niklason	Founder	20.8yrs	US$2.63m	0.19% $ 1.4m
Max Wallace	Independent Director	19.3yrs	US$76.76k	0.052% $ 375.7k
Brady Dougan	Director	19.8yrs	US$71.76k	0.41% $ 3.0m
Susan Windham-Bannister	Independent Director	3.2yrs	US$71.76k	0% $ 0
Todd Pope	Independent Director	no data	US$76.76k	0% $ 0
Kathleen Sebelius	Independent Chairman of the Board	9.1yrs	US$96.76k	0.033% $ 239.8k
Michael Constantino	Independent Director	no data	US$79.26k	0.0099% $ 71.9k
Diane Seimetz	Independent Director	2.3yrs	US$71.76k	0% $ 0
Emery Brown	Independent Director	3.2yrs	US$71.76k	0% $ 0
C. Green	Independent Director	2.1yrs	US$71.76k	0% $ 0
John Bamforth	Director	less than a year	geen gegevens	geen gegevens
Keith Jones	Director	less than a year	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HUMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Humacyte Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Key Executive notifies of intention to sell stock

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Recent updates

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Humacyte, Inc. Announces Allowance of U.S. Patent Covering BioVascular Pancreas

Price target increased by 20% to US$13.17

Key Executive notifies of intention to sell stock

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

New minor risk - Insider selling

Humacyte, Inc. Acellular Tissue Engineered Vessel Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Price target increased by 13% to US$9.30

Consensus revenue estimates increase by 13%

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022